By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Eisai Inc. 

100 Tice Boulevard

Woodcliff Lake  New Jersey  07677  U.S.A.
Phone: 201-692-1100 Fax: 201-692-1804


SEARCH JOBS
Headquartered in Woodcliff Lake, New Jersey, Eisai Inc. was established in 1995 and is ranked among the top-20 U.S. pharmaceutical companies (based on retail sales). The company began marketing its first product in the United States in 1997 and has rapidly grown to become a fully integrated pharmaceutical business. Eisai’s areas of commercial focus include neurology, gastrointestinal disorders and oncology/critical care. The company serves as the U.S. pharmaceutical operation of Eisai Co., Ltd., a research-based human health care (hhc) company that discovers, develops and markets products throughout the world.

Eisai has a global product creation organization that includes U.S.-based R&D facilities in Maryland, Massachusetts, New Jersey, North Carolina and Pennsylvania as well as manufacturing facilities in Maryland and North Carolina. The company’s areas of R&D focus include neuroscience; oncology; vascular, inflammatory and immunological reaction; and antibody-based programs. For more information about Eisai, please visit www.eisai.com.

For more information about Eisai, please visit www.eisai.com


Key Statistics


Email:
Ownership: Subsidiary

Web Site: Eisai Inc.
Employees: Approximately 2,600
Symbol: ESALF.PK
 



Industry
Pharmaceutical






Company News
Eisai Inc. (ESALF.PK) To Present New Data On Several Oncology Compounds At ASCO 2015 5/14/2015 11:18:17 AM
Eisai Inc. (ESALF.PK) And Glenmark Pharmaceuticals Reach Settlement Over Generic Version Of BANZEL (rufinamide) 4/30/2015 11:22:46 AM
Helsinn Group And Eisai Inc. (ESALF.PK) Announce Inclusion of AKYNZEO (netupitant/palonosetron) In 2015 NCCN Antiemesis Guidelines 4/15/2015 3:38:41 PM
Eisai Inc. (ESALF.PK) And Genomics Plc To Collaborate In Analyses Of Large-Scale Genotype/Phenotype Data To Inform Drug Development 4/13/2015 11:00:21 AM
Eisai Inc. (ESALF.PK) Release: LENVIMA (lenvatinib) Now Available Through Two Specialty Pharmacies, Accredo And Biologics, Inc. 2/27/2015 7:00:54 AM
Eisai Inc. (ESALF.PK) Release: Topline Results Of Phase 3 Trial Show Eribulin Mesylate Injection Meets Primary Endpoint Of Overall Survival In Advanced Soft Tissue Sarcoma 2/25/2015 6:48:17 AM
Eisai Inc. (ESALF.PK) Launches New Savings Card To Increase Access And Affordability Of BELVIQ® (lorcaserin HCl) CIV 1/20/2015 8:11:34 AM
Eisai Inc. (ESALF.PK) Presents New Data On Perampanel And Rufinamide At The 68th Annual American Epilepsy Society Meeting 12/8/2014 9:06:06 AM
Eisai Inc. (ESALF.PK) Release: New Research On Eribulin Mesylate And Netupitant/Palonosetron To Be Presented At Annual San Antonio Breast Cancer Symposium 12/2/2014 11:01:36 AM
Eisai Inc. (ESALF.PK) Doubles Down On U.K. Packaging Plant With £8 Million Investment; Boost Employment By 10% 11/26/2014 5:44:17 AM
12345678910...
//-->